NeoGenomics, Inc. revised earnings guidance for the full year ending December 31, 2023. For the year, the company expected consolidated revenue to be in the range of $585 million to $592 million against the previous guidance range of $565 million to $575 million. Net loss to be in the range of $95 million to $89 million against the previous guidance range of $107 million to $100 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.87 USD | +3.97% |
|
+5.32% | -14.28% |
05-28 | NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO | CI |
05-02 | North American Morning Briefing : Stock Futures -3- | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.28% | 1.7B | |
-18.02% | 8.42B | |
+69.46% | 4.35B | |
+7.88% | 2.74B | |
-56.54% | 1.78B | |
-16.69% | 1.47B | |
+17.87% | 1.19B | |
-49.60% | 1.03B | |
-21.78% | 927M | |
+10.83% | 926M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023